PHARMABIZ.com
india's most comprehensive pharma portal

Indoco receives EIR from US FDA for its API manufacturing facility at Patalganga

Our Bureau, Mumbai
Friday, December 12, 2025, 14:15 Hrs [IST]

Indoco Remedies Limited (Indoco), a fully integrated, research-oriented pharmaceutical company, announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (FDA) for its active pharmaceutical ingredients (API) manufacturing facility located at Patalganga, following a successful Inspection of the said facility from 15th September, 2025 to 19th September, 2025.

Aditi Panandikar, managing director, Indoco said, “We are pleased to have received the EIR from the US FDA for our API manufacturing facility located at Patalganga. This further reinforces our commitment to upholding the highest standards of quality and compliance, delivering trusted healthcare solutions to patients worldwide.”

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The company’s turnover is US$ 180 million with a human capital of over 6,000 employees, including over 400 skilled scientists and field staff who are the strength of the organization.

The company has 11 manufacturing facilities, 7 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including US FDA and UK MHRA.